The ALPHA study is a first-in-human phase I trial (NCT03939026) of ALLO-501 and ALLO-647 for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) or follicular lymphoma (FL). ALLO-501 is an allogeneic CAR T-cell therapy product that is generated by introducing an anti-CD19 CAR molecule into healthy donor T cells.
Tag: ASCO20
Chemotherapy-Free Approaches in Follicular and Mantle Cell Lymphomas – The ASCO Post
Acute Myeloid Leukemia Resource Center
Acute Myeloid Leukemia Resource Center
CBD, Geriatric Assessments for Cutting Cancer Tx Side Effects
Cary Presant, MD, says the more information the better
Experts Spotlight Ongoing Efforts Evaluating Immunotherapy in Sarcoma
Despite encouraging data shown in some subtypes, there is still a lot of work that still needs to be done with determining the optimal use for immunotherapy in patients with sarcoma, a population that has historically been difficult to treat.
Evaluating Unconscious Bias: Speaker Introductions at an International Oncology Conference
PURPOSE In a professional setting, the introduction of female speakers without their professional title may have an impact on the public’s perception of the female speaker. We examined how professional titles were used during speakers’ introductions at the ASCO Annual Meeting. METHODS We conducted a retrospective, observational study of video-archived speaker introductions at the 2017 and 2018…
Experts Spotlight Ongoing Efforts Evaluating Immunotherapy in Sarcoma
Despite encouraging data shown in some subtypes, there is still a lot of work that still needs to be done with determining the optimal use for immunotherapy in patients with sarcoma, a population that has historically been difficult to treat.
Meeting Library | Meeting Library
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2020 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Meeting Library | Meeting Library
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2020 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
ASCO: Cabozantinib and Atezolizumab in Urothelial Cancer
Interview by Nazli Dizman MD Interview with Sumanta Kumar Pal MD